A Toxin-Based Delivery System That Shuttles Peptide Drugs Into the Cell Nucleus | Research

The takeaway

A non-toxic form of Pseudomonas exotoxin A delivers peptide cargos directly to the nucleus, inhibiting the cancer-driving c-Myc protein at nanomolar concentrations.

Nanomolar
c-Myc inhibition achieved by PNDD-delivered peptide, far exceeding conventional delivery approaches

What the researchers found

PNDD1 delivers the c-Myc inhibitor peptide H1 to the nucleus and inhibits c-Myc-dependent transcription at nanomolar concentration, far exceeding the activity of H1 with conventional CPPs.

Why it matters

Many cancer targets like c-Myc are in the nucleus, but most delivery systems only reach the cytoplasm. PNDD is the first system to efficiently deliver therapeutic peptides specifically to the nucleus.

The numbers in context

Nanomolar potency (vs µM for CPP); killed DLBCL lines; spared normal B cells; delivered GST-sized cargo to nucleus

How the study worked

Fusion protein construction, nuclear localization tracking, c-Myc transcription inhibition assays, comparison with CPP-conjugated controls.

Who was studied

Tumor cell lines and patient-derived DLBCL cells vs normal B cells

What this study cannot tell us

In vitro proof-of-concept. Immunogenicity of the bacterial exotoxin fragment needs assessment. In vivo delivery efficiency unknown.

How to read the evidence

In vitro demonstration with strong functional data. Novel approach but early stage.

When this study was published

Published in 2020. Nuclear peptide delivery remains an active research challenge.

The bigger picture

Nuclear-targeted peptide delivery could unlock an entire class of previously undruggable nuclear targets in cancer and other diseases.

Questions still open

Would PNDD elicit immune responses in vivo due to its bacterial origin?
Can this system deliver peptides to specific nuclear compartments?
What is the therapeutic window between nuclear delivery and cytotoxicity?

Common questions

Why is getting drugs into the cell nucleus so hard?

Most drug delivery systems only get cargo into the cell's cytoplasm. The nucleus has its own membrane barrier with selective entry controls (nuclear pores). PNDD exploits a natural toxin pathway that goes directly from the cell surface to the nucleus.

What is c-Myc and why target it?

c-Myc is a transcription factor that drives many cancers by turning on genes for cell growth and division. Despite being one of the most important cancer targets, it has been considered 'undruggable' because it's inside the nucleus and lacks a traditional drug-binding pocket.

Read the original research

Targeting c-Myc with a novel Peptide Nuclear Delivery Device.

Scientific reports, 10(1), 17762

View on PubMed ↗Publisher’s paper ↗

Citation

Ting, Trinda Anne; Chaumet, Alexandre; Bard, Frederic Andre. (2020). Targeting c-Myc with a novel Peptide Nuclear Delivery Device.. Scientific reports, 10(1), 17762. https://doi.org/10.1038/s41598-020-73998-x